Robert M. Zielinski, MD; William D. Lawrence, MD
The hypereosinophilic syndrome is defined by unexplained eosinophilia (eosinophil count > 1.5 x 109/L) lasting more than 6 months (1). Characteristic clinical features include congestive heart failure with endocardial fibrosis (2), venous and arterial thromboembolism, neuropsychiatric dysfunction (3), anemia, and thrombocytopenia. These disease manifestations have been attributed to tissue infiltration by eosinophils and the direct toxic effects of the products of eosinophilic granules (1, 2, 4).
Therapy has been directed at lowering the absolute eosinophil count to below 1 x 109/L with prednisone and the cytotoxic agent, hydroxyurea (1, 5). This therapeutic approach appears to have dramatically improved median survival
Zielinski RM, Lawrence WD. Interferon-α for the Hypereosinophilic Syndrome. Ann Intern Med. ;113:716–718. doi: 10.7326/0003-4819-113-9-716
Download citation file:
Published: Ann Intern Med. 1990;113(9):716-718.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use